EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Ikena Oncology's enterprise value is $-83.42 Mil.
Ikena Oncology's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was $-74.54 Mil. Therefore, Ikena Oncology's EV-to-EBITDA for today is 1.12.
The historical rank and industry rank for Ikena Oncology's EV-to-EBITDA or its related term are showing as below:
IKNA'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -21.55 Med: 0.06 Max: 4.79
Current: 1.12
During the past 5 years, the highest EV-to-EBITDA of Ikena Oncology was 4.79. The lowest was -21.55. And the median was 0.06.
IKNA's EV-to-EBITDA is ranked better than 68.22% of 450
companies
in the Biotechnology industry
Industry Median: 9.57
vs IKNA: 1.12
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Ikena Oncology EV-to-EBITDA Historical Data
The historical data trend for Ikena Oncology's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Ikena Oncology's EV-to-EBITDA
For the Biotechnology subindustry, Ikena Oncology's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ikena Oncology's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ikena Oncology's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Ikena Oncology's EV-to-EBITDA falls into.
Ikena Oncology EV-to-EBITDA Calculation
Ikena Oncology's EV-to-EBITDA for today is calculated as:
Ikena Oncology's current Enterprise Value is $-83.42 Mil.
Ikena Oncology's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-74.54 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Ikena Oncology's PE Ratio for today is calculated as:
Ikena Oncology's share price for today is $1.33.
Ikena Oncology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.570.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Ikena Oncology's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Ikena Oncology (Ikena Oncology) Business Description
Ikena Oncology Inc is a targeted oncology company developing precision medicines tailored to biomarker-defined patient groups with specific unmet needs. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway. The Hippo pathway is genetically altered in approximately 10% of human cancers and is widely accepted as a prevalent driver of cancer pathogenesis and a mediator of poor outcomes for patients. its other product candidates are IK-175 and IK-595.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
IKNA has been successfully added to your 